Task: gap020 | Last Updated: 2026-03-15 | Kind: gap-analysis | Total Gaps Identified: 10
Knowledge Gap: What is the relationship between progranulin deficiency and TDP-43 aggregation in frontotemporal dementia?
This page explores the mechanistic link between progranulin (GRN) haploinsufficiency and TDP-43 proteinopathy in frontotemporal dementia (FTD), a critical knowledge gap with significant therapeutic implications.
Frontotemporal dementia (FTD) is a clinically and pathologically heterogeneous disorder characterized by progressive degeneration of the frontal and temporal lobes. Approximately 40-50% of FTD cases exhibit TDP-43 pathology (FTD-TDP), making it one of the most common underlying proteinopathies in FTD[1]. Heterozygous loss-of-function mutations in the GRN gene (progranulin) are a major cause of familial FTD, accounting for 5-10% of all FTD cases and up to 20% of familial cases[2].
The discovery that GRN mutations cause FTD through haploinsufficiency (reduced progranulin protein levels) rather than a toxic gain-of-function has profound implications for understanding disease mechanisms and developing therapies.
The GRN gene, located on chromosome 17q21.31, encodes progranulin, a 593-amino acid secreted glycoprotein[3]. Progranulin is composed of 7.5 tandem repeats of a highly conserved 12-cysteine granulin domain. It is widely expressed in neurons, microglia, and peripheral tissues.
Progranulin participates in multiple cellular processes[4]:
In the CNS, progranulin is expressed primarily in neurons and microglia. It plays essential roles in:
TAR DNA-binding protein 43 (TDP-43) is a 414-amino acid nuclear protein encoded by the TARDBP gene[1:1]. Under normal conditions, TDP-43 localizes to the nucleus where it regulates RNA splicing, stability, and transport.
In FTD-TDP and ALS, TDP-43 mislocalizes from the nucleus to the cytoplasm, where it forms insoluble aggregates. This pathology is observed in:
Normal TDP-43 functions include[1:2]:
Multiple lines of evidence support a mechanistic link between progranulin deficiency and TDP-43 pathology[5][3:1]:
The leading model proposes that progranulin deficiency causes[4:1]:
Some studies suggest the relationship may be indirect[6]:
| Approach | Stage | Company | Status |
|---|---|---|---|
| AAV-mediated GRN delivery | Preclinical | Various | Research |
| Recombinant progranulin | Preclinical | - | Research |
| Small molecule upregulators | Discovery | - | Early stage |
| Trial | Phase | Focus | Status |
|---|---|---|---|
| NCT05566647 | Observational | GRN carrier biomarker study | Recruiting |
| NCT05682391 | Preclinical | AAV-GRN efficacy | Preclinical |
Ward et al. TDP-43 proteinopathies (2019). 2019. ↩︎ ↩︎ ↩︎
Cruts et al. GRN mutations and TDP-43 pathology (2006). 2006. ↩︎
Baker et al. Progranulin mutations in FTD (2006). 2006. ↩︎ ↩︎
Gao et al. Progranulin and lysosomal function (2021). 2021. ↩︎ ↩︎
Chen et al. Progranulin deficiency causes TDP-43 pathology. 2024. ↩︎
Loppio et al. FTD-GRN: clinical features and genetics (2023). 2023. ↩︎
Zhao et al. GGA3 depletion and lysosomal dysfunction. 2024. ↩︎
Halbgebauer et al. CSF progranulin as biomarker in FTD (2024). 2024. ↩︎
Parker et al. Microglial progranulin and neuronal TDP-43. 2024. ↩︎
Smith et al. AAV-progranulin delivery reduces TDP-43 pathology. 2024. ↩︎